Avita Medical (RCEL) said late Thursday it named Chairman Cary Vance to the additional post of interim chief executive, effective immediately, replacing CEO Jim Corbett.
The company will consider internal and external candidates, including Vance, for the role of permanent CEO.
Avita Medical also said it expects preliminary Q3 revenue of around $17 million. Analysts surveyed by FactSet expect $19.2 million.
The company's shares were down nearly 20% in recent premarket activity Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.